Unlabelled: BACKGROUND AND OBJECTIVES We have tested whether the complement activation products SC5b-9 and C3a-desArg are useful to distinguish complicated (CPE) from uncomplicated parapneumonic effusions (UPE).
Design: A total of 66 patients were enrolled in the study: 5 with empyema, 19 with CPE, 12 with UPE, and 30 transudates who served as controls. SC5b-9 and C3a-desArg were measured by commercial ELISA tests, and their performances were evaluated using receiver operating characteristic (ROC) analysis.
Results: Patients with CPE had higher mean levels of pleural SC5b-9 (8,218 microg/l) and C3a-desArg (8,790 microg/l) than those with UPE (2,227 and 3,772 microg/l, respectively; p < 0.0001), whereas concentrations in the latter were comparable with controls for the SC5b-9 test. Empyemas had a wide range of pleural complement activation product values. Pleural SC5b-9 and C3a-desArg showed very high diagnostic accuracy in the diagnosis CPE (90.3 and 77.8%, respectively) when corresponding cutoff points of 2,000 and 4,000 microg/l were used. In a stepwise logistic regression analysis, the combination of SC5b-9 >/=2,000 microg/l, LDH >/=1,000 U/l and a pleural polymorphonuclear percentage >/=85% provided the highest discriminative power for the diagnosis of CPE (area under ROC curve 0.97).
Conclusion: This pilot study suggests that measurement of pleural SC5b-9 can be useful in the workup of patients with a parapneumonic effusion in order to differentiate CPE from UPE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000029543 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eculizumab for pediatric dense deposit disease: A case report and literature review.
Clin Nephrol Case Stud
December 2020
Department Renal Replacement Therapy, Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya-shi, Aichi-ken, Japan.
Dense deposit disease (DDD), a subtype of complement component 3 (C3) glomerulopathy (C3G), results from alternative complement pathway hyperactivity leading to membrane attack complex formation. DDD treatment strategies are limited. We report a case of a 13-year-old girl diagnosed with DDD at 9 years of age, with nephritic and nephrotic syndrome and C3 nephritic factor-negative alternative complement pathway activation.
View Article and Find Full Text PDFPleural fluid tests to identify complicated parapneumonic effusions.
Curr Opin Pulm Med
July 2010
Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain.
Purpose Of Review: Approximately 20% of patients with community-acquired pneumonia develop pleural effusions. In about 30% of these patients, the condition progresses to complicated parapneumonic effusion (CPPE) or to empyema. Pleural fluid analysis may aid decision-making for drainage in nonpurulent pleural fluids.
View Article and Find Full Text PDFVascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement.
J Infect Dis
April 2006
Medical Molecular Biology Unit, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: Vascular leakage and shock are the major causes of death in patients with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Thirty years ago, complement activation was proposed to be a key underlying event, but the cause of complement activation has remained unknown.
Methods: The major nonstructural dengue virus (DV) protein NS1 was tested for its capacity to activate human complement in its membrane-associated and soluble forms.
Pleural SC5b-9: a test for identifying complicated parapneumonic effusions.
Respiration
September 2000
Department of Internal Medicine, University Hospital Arnau de Vilanova, University of Lleida, Spain.
Unlabelled: BACKGROUND AND OBJECTIVES We have tested whether the complement activation products SC5b-9 and C3a-desArg are useful to distinguish complicated (CPE) from uncomplicated parapneumonic effusions (UPE).
Design: A total of 66 patients were enrolled in the study: 5 with empyema, 19 with CPE, 12 with UPE, and 30 transudates who served as controls. SC5b-9 and C3a-desArg were measured by commercial ELISA tests, and their performances were evaluated using receiver operating characteristic (ROC) analysis.
Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions.
Int J Tuberc Lung Dis
January 2000
Department of Internal Medicine, University Hospital Arnau de Vilanova, University of Lleida, Spain.
Objective: To determine whether measurement of the complement activation products SC5b-9 and C3a-desArg in pleural fluid can reliably differentiate tuberculous from malignant pleural effusions.
Design: Twenty-four patients with tuberculous pleuritis, 29 with malignant pleural effusion, and 30 control subjects with transudates were enrolled in the study. SCSb-9 and C3a-desArg were measured in pleural fluid using commercial ELISA tests, and their performances were evaluated using receiver operating characteristic (ROC) analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!